Treatment modality affects allograft-derived Schwann cell phenotype and myelinating capacity.
We used peripheral nerve allografts, already employed clinically to reconstruct devastating peripheral nerve injuries, to study Schwann cell (SC) plasticity in adult mice. By modulating the allograft treatment modality we were able to study migratory, denervated, rejecting, and reinnervated phenotypes in transgenic mice whose SCs expressed GFP under regulatory elements of either the S100b (S100-GFP) or nestin (Nestin-GFP) promoters. Well-differentiated SCs strongly expressed S100-GFP, while Nestin-GFP expression was stimulated by denervation, and in some cases, axons were constitutively labeled with CFP to enable in vivo imaging. Serial imaging of these mice demonstrated that untreated allografts were rejected within 20 days. Cold preserved (CP) allografts required an initial phase of SC migration that preceded axonal regeneration thus delaying myelination and maturation of the SC phenotype. Mice immunosuppressed with FK506 demonstrated mild subacute rejection, but the most robust regeneration of myelinated and unmyelinated axons and motor endplate reinnervation. While characterized by fewer regenerating axons, mice treated with the co-stimulatory blockade (CSB) agents anti-CD40L mAb and CTLAIg-4 demonstrated virtually no graft rejection during the 28 day experiment, and had significant increases in myelination, connexin-32 expression, and Akt phosphorylation compared with any other group. These results indicate that even with SC rejection, nerve regeneration can occur to some degree, particularly with FK506 treatment. However, we found that co-stimulatory blockade facilitate optimal myelin formation and maturation of SCs as indicated by protein expression of myelin basic protein (MBP), connexin-32 and phospho-Akt.
Hayashi
Ayato
A
Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8238, Saint Louis, MO 63110, USA.
Moradzadeh
Arash
A
Tong
Alice
A
Wei
Cindy
C
Tuffaha
Sami H
SH
Hunter
Daniel A
DA
Tung
Thomas H
TH
Parsadanian
Alexander
A
Mackinnon
Susan E
SE
Myckatyn
Terence M
TM
D000818:Animals; D023201:CD40 Ligand / Q000378:metabolism; D017630:Connexins / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D006084:Graft Rejection / Q000517:prevention & control; D049452:Green Fluorescent Proteins / Q000096:biosynthesis / Q000235:genetics; D007381:Intermediate Filament Proteins / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D046529:Microscopy, Electron, Transmission / Q000379:methods; D009043:Motor Activity; D004676:Myelin Basic Protein / Q000378:metabolism; D009416:Nerve Regeneration / Q000502:physiology*; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D064231:Nestin; D010641:Phenotype; D009418:S100 Proteins / Q000235:genetics / Q000378:metabolism; D012583:Schwann Cells / Q000378:metabolism / Q000502:physiology* / Q000648:ultrastructure; D020426:Sciatic Neuropathy / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D016559:Tacrolimus / Q000494:pharmacology; D013997:Time Factors; D014184:Transplantation, Homologous / Q000502:physiology*; D000097002:Gap Junction beta-1 Protein
D023201:CD40 Ligand; D017630:Connexins; D049452:Green Fluorescent Proteins; D007381:Intermediate Filament Proteins; D004676:Myelin Basic Protein; D009419:Nerve Tissue Proteins; D064231:Nestin; D009418:S100 Proteins; D016559:Tacrolimus; D000097002:Gap Junction beta-1 Protein; C577485:Nes protein, mouse